Vevo
Johnny Yu is the Chief Scientific Officer and Co-founder of Vevo Therapeutics, a biotechnology company focused on single-cell drug discovery, utilizing an in vivo drug discovery platform and advanced AI models to develop innovative treatments. Prior to this role, Johnny Yu was a Ph.D. student in Dr. Hani Goodarzi's lab at UCSF, where research involved RNA Binding Proteins and single-cell RNA sequencing, leading to a significant publication in Cancer Discovery 2020. Earlier experiences include working as a Research Associate II at the Broad Institute, where functional characterization of GWAS-derived SNPs related to Atrial Fibrillation was conducted, and as an Associate Scientist I at Biogen Idec, focusing on technical development and downstream processes for antibody purification. Johnny Yu obtained a Ph.D. in Biomedical Sciences from the University of California, San Francisco, following a Bachelor of Science in Biochemistry from Tufts University.
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.